Prevalencia de artralgias y mialgias en pacientes con cáncer de mama en tratamiento con inhibidores de la aromatasa

Introduction

Aromatase inhibitors have been incorporated within the standard of care for post-menopausal women with hormone receptor-positive breast cancer. The FDA has approved three aromatase inhibitors: anastrazole (Arimidex^®), exemestane (Aromasin^®), and letrozole (Femara^®). Prospective studies have shown that the skeletomuscular adverse effects of these agents have increased treatment-related morbidity, resulting in their discontinuation of use.

To evaluate the presence and/or exacerbation of polyarthralgia and myalgia in patients treated with aromatase inhibitors

Method

The study included 86 patients from the ISSSTEP hospital, with an age ranging from 34-87 years, with a histopathological diagnosis of breast cancer, immunohistochemistry confirmation of positive hormone receptors, and on treatment with an aromatase inhibitor.